Clovis buys Italian biopharma for at least $200M

11/21/2013 | Genetic Engineering & Biotechnology News

Clovis Oncology agreed to acquire Italy-based Ethical Oncology Science for $200 million upfront plus milestone fees. The deal gives Clovis rights to EOS' lead cancer drug candidate, lucitanib, which is in Phase I/IIa trials. "We have been interested in lucitanib for some time and are pleased to have acquired EOS to add this program to our portfolio. It is highly consistent with our focus on developing targeted therapies that provide meaningful benefit to specific patient populations," Clovis President and CEO Patrick J. Mahaffy said.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR CLINICAL RESEARCH - 14000003MB
Abbott
Santa Clara, CA
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC